RxDoctor Payments Data

Saron Belay, PA

Physician Assistant · Forest Hill, MDNPI 1306432653

Payments from drug & device makers

$4,676in general payments, 2019–2025

Across 195 payments — averaging $23.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$639
  • Johnson & Johnson$532
  • Astellas Pharma US Inc$498
  • Sumitomo Pharma America, Inc.$385
  • Urovant Sciences Inc$368
  • Medtronic$368
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$4,57698%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,676 in reported general payments places this provider in the 90th percentile of 2,567 physician assistant providers in Maryland.

See all physician assistant providers in Maryland

Medicare billing

Part B allowed, 2024
$31,035
Medicare patients
136
Services billed
538

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide25$394,052
MyrbetriqMirabegron62$37,693
GemtesaVibegron22$22,659
Tamsulosin Hcl289$5,725
Bethanechol Chloride20$3,443
Solifenacin Succinate22$2,165
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst78$1,335
Oxybutynin Chloride ErOxybutynin Chloride36$1,143
NitrofurantoinNitrofurantoin Macrocrystal23$935
Finasteride41$572
Dutasteride14$416
Alfuzosin Hcl ErAlfuzosin Hcl12$277
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav25$253
Ciprofloxacin Hcl38$247
Doxycycline Hyclate13$225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$498$431,74587 claims
Sumitomo Pharma America, Inc.Gemtesa$385$22,65922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,567 physician assistant providers in Maryland.

Other physician assistant in Forest Hill

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →